@article{3089946,
    title = "Cinacalcet as alternative treatment for Primary hyperparathyroidism: Achievements and prospects",
    author = "Duntas, L.H. and Stathatos, N.",
    journal = "Endocrine Development",
    year = "2011",
    volume = "39",
    number = "3",
    pages = "199-204",
    publisher = "Humana Press Inc.",
    doi = "10.1007/s12020-011-9452-7",
    keywords = "1,25 dihydroxyergocalciferol;  alendronic acid;  bisphosphonic acid derivative;  calcimimetic agent;  calcium;  calcium sensing receptor;  cinacalcet;  cyclin D1;  ibandronic acid;  pamidronic acid;  parathyroid hormone;  placebo;  raloxifene;  selective estrogen receptor modulator;  Wnt protein;  zoledronic acid, Albright syndrome;  alternative medicine;  bone density;  calcium blood level;  cardiovascular risk;  deep vein thrombosis;  disease severity;  dose response;  drug cost;  drug dose titration;  drug efficacy;  drug mechanism;  drug safety;  drug tolerability;  human;  hypercalcemia;  morbidity;  mortality;  multiple endocrine neoplasia;  pathogenesis;  primary hyperparathyroidism;  priority journal;  review;  secondary hyperparathyroidism;  thrombophlebitis;  treatment duration;  treatment indication",
    abstract = "Primary hyperparathyroidism (pHPT), which most frequently occurs asymptomatically, is a common endocrine disease associated with increased morbidity and mortality. The newly introduced management guidelines as well as the recent availability of the first calcimimetic offer a highly promising therapeutic option for patients with pHPT. Cinacalcet, the first available calcimimetic, increases the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, thereby safely reducing serum calcium and PTH concentrations in patients with mild-tomoderate pHPT, intractable disease, and also parathyroid carcinoma. Cinacalcet has proved efficient in short-and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT. These results encompass a wide spectrum of disease severity. Results are pending as to whether cinacalcet decreases mortality and morbidity in pHPT, confirmation of which would conclusively recommend this drug as a valid alternative to surgery. © Springer Science+Business Media, LLC 2011."
}